Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Form 8-K was filed by Jaguar Health, Inc. on January 18, 2018. The Company is an emerging growth company incorporated in Delaware. The report primarily serves as a Regulation FD disclosure regarding an upcoming investor conference call.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding a corporate event rather than a periodic financial statement.
Material Changes
No material financial changes or operational updates are detailed within the body of this filing. The report announces the scheduling of a conference call to discuss future activities.
Guidance, Outlook, and Management Commentary
Management has scheduled a conference call for Monday, January 22, 2018, at 4:15 p.m. EST / 1:15 p.m. PST. The call will provide updates on:
- Commercial activities.
- Educational initiatives.
- Product development activities for Jaguar Health and its wholly-owned subsidiary, Napo Pharmaceuticals, Inc. (focused on human health).
A press release detailing this announcement is included as Exhibit 99.1.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) for specific details on the conference call agenda.
- Confirm the date and time of the conference call: January 22, 2018, at 4:15 p.m. EST.
- Note that this filing contains no new financial data; investors should refer to the most recent 10-K or 10-Q for financial metrics.
- Identify Napo Pharmaceuticals, Inc. as the Company's subsidiary focused on human health.